Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?

Vincent Ting Fung Cheung1,2, Tarun Gupta1,2, Anna Olsson-Brown3,4, Sreedhar Subramanian5, Sarah Christina Sasson1,2, Jonathan Heseltine3, Eve Fryer3, Elena Collantes3, Joseph J. Sacco3,4, Munir Pirmohamed3, Paul Kleanner1,2, Mark Tuthill1, Andrew S. Protheroe2,7, Meenali Chitnis7, Benjamin Peter Fairfax2,7, Miranda Jane Payne2,7, Mark Ross Middleton2,7 and Oliver Brain1,2

BACKGROUND: Immune checkpoint inhibitors (ICI) improve survival but cause immune-related adverse events (irAE). We sought to determine if CTCAE classification, IBD biomarkers/endoscopic/histological scores correlate with irAE colitis outcomes.

METHODS: A dual-centre retrospective study was performed on patients receiving ICI for melanoma, NSCLC or urothelial cancer from 2012 to 2018. Demographics, clinical data, endoscopies (reanalysed using Mayo/Ulcerative Colitis Endoscopic Index of Severity (UCEIS) scores), histology (scored with Nancy index) and treatment outcomes were analysed.

RESULTS: In all, 1074 patients were analysed. Twelve percent (134) developed irAE colitis. Median patient age was 66, 59% were male. CTCAE diarrhoea grade does not correlate with steroid/infliximab use. G3/4 colitis patients are more likely to need infliximab (p < 0.0001) but colitis grade does not correlate with steroid duration. CRP, albumin and haemoglobin do not correlate with severity. The UCEIS (p = 0.008) and Mayo (p = 0.016) scores correlate with severity/infliximab requirement. Patients with higher Nancy indices (3/4) are more likely to require infliximab (p = 0.03).

CONCLUSIONS: CTCAE assessment does not accurately reflect colitis severity and our data do not support its use in isolation, as this may negatively impact timely management. Our data support utilising endoscopic scoring for patients with >grade 1 CTCAE disease, and demonstrate the potential prognostic utility of objective histologic scoring.

British Journal of Cancer (2020) 123:207–215; https://doi.org/10.1038/s41416-020-0882-y

© The Author(s) 2020 Revised: 6 April 2020 Accepted: 24 April 2020 Published online: 18 May 2020

Published on behalf of Cancer Research UK
enterocolitis patients had GI symptoms presenting after ICI administration. Patients where an alternative diagnosis was made, e.g. infection or use of non-steroidal anti-inflammatory drugs, were excluded. Monitoring for ICI response was generally performed every 3 months.

Definition of diarrhoea and irAE colitis
We conducted a comprehensive review of the EPR and oncology prescribing databases to confirm the diagnosis of ICI-related diarrhoea or colitis based on the decision of the treating oncologist or gastroenterologist. Diarrhoea was defined on CTCAE version 5.0\(^1\) on review during data collection using the primary data. irAE colitis was defined as diarrhoea requiring steroid/infliximab therapy for resolution and/or with endoscopic/histological confirmation. Oncology guidelines on managing ICI-related colitis do not currently mandate endoscopic assessment, and therefore patients are mostly initiated on steroid treatment prior to endoscopy.\(^{12-14}\) Onset of colitis was defined from start of ICI to date of diarrhoea.

Severity of colitis
There is no standard way of assessing severity apart from CTCAE, which as a predominantly subjective clinical score is of uncertain value. Patients were, therefore, divided into severity categories depending on the nature and length of treatment required to achieve colitis resolution. A standard weaning steroid course for an IBD flare is 60 days so we used this as one delineator of outcome and severity. Patients were divided into three categories: (1) mild-moderate colitis where diarrhoea settled rapidly following a course of steroids ≤60 days; (2) refractory or moderate-severe colitis requiring steroids >60 days; and (3) severe colitis requiring infliximab ‘rescue therapy’.

IBD biomarkers
Markers commonly used in UC to assess severity and prognosticate (CRP and haemoglobin in Truelove & Witts score,\(^5\) or albumin in the Ho index\(^2^3\)) were analysed to determine if they correlated with severity of colitis and treatment outcome.

Endoscopic analysis
We analysed the subset of patients for whom endoscopic data were available (n = 40, 30%) in a blinded fashion with Joint Advisory Group on gastrointestinal endoscopy (JAG)-accredited endoscopists (V.T.F.C. and O.B.) separately scoring the images taken at endoscopy on UCEIS\(^2^4\) and Mayo scores\(^2^5\) (Supplementary Fig. 1a, b). Where there was disagreement, V.T.F.C. and O.B. assessed the images again and came to a consensus. Both endoscopists and pathologists were blinded during scoring to clinical outcome.

Histological analysis
We analysed a subset of patients for whom histological slides were available (n = 45). Two expert GI pathologists, E.F. and E.C., separately scored the slides on the presence (or absence of) ulceration, acute inflammatory cells infiltrate and chronic inflammatory infiltrate then calculated the Nancy index\(^19\) (Supplementary Fig. 1c). The histopathologists then assigned an overall histological pattern grading to each patient based on one of the following types:

- focal active colitis—occasional foci of acute inflammation, in the absence of chronic inflammation or significant crypt injury;
- lymphocytic colitis—increase in intraepithelial and lamina propria lymphocytes, in the absence of crypt architectural distortion;
- collagenous colitis—increase in thickness of the subepithelial collagen plate and increased lamina propria lymphocytes, in the absence of crypt architectural distortion;
IBD-like—active chronic inflammation with goblet cell depletion and crypt architectural distortion;

Non-steroidal anti-inflammatory drug (NSAID) /infectious-like—predominantly acute, superficial inflammation with attenuation of crypt and/or surface epithelium.

The histological specimens analysed against treatment outcome were all acquired at the index scope when diagnosing irAE colitis, and prior to infliximab use. There was a discrepancy between the number of endoscopies (n = 40) and histopathology scored (n = 45) because only endoscopies with adequate images were included in the analysis. We also analysed all available paired data (from both index and follow-up sigmoidoscopies) to determine whether endoscopic scoring correlates in general with histological scoring in irAE enterocolitis (n = 80).

Statistical analysis
Continuous data are presented with mean (with range) or median and interquartile range. Non-continuous data are presented as number (percentage), or median and interquartile range. Statistical analysis was performed using Graphpad PRISM™ (Ver 8.1) and IBM SPSS™ (Ver 25) software. A p value < 0.05 was considered statistically significant, and where multiple comparisons were performed a Bonferroni correction was made as detailed in supplementary data.

RESULTS
Presentation and treatment of irAE colitis
A total of 1074 patients were identified across the two centres (Table 1) with 12% (n = 134) of patients developing colitis with a median time of onset 60 days (IQR 28–88 days). There was a predominance of male patients in the cohort (59%), and a median age of 66 (Supplementary Table 1). Patients who developed G4 diarrhoea did so earlier after ICI induction (median onset 33 days) than those who developed milder G1/2 diarrhoea (median onset 60 days). Sixty-three percent of patients were admitted, with the median inpatient stay being 7 days. Time to irAE colitis, hospital stays related to colitis and treatments used are shown in Table 1.

Patients treated with combination therapy had a significantly higher risk of developing colitis vs. those treated with monotherapy (Fig. 1a; 32% vs 9%; p < 0.0001). Treatment with single-agent ICI resulted in a later onset of colitis compared to those patients given combination therapy (Fig. 1b). Twenty-two percent of patients received rescue therapy with infliximab either as single or multiple doses (Fig. 1c) at a median of 50 days (Fig. 1c inset), with three undergoing a colectomy (2.3%; two had ipilimumab and one had combination). Median time to giving infliximab was 13.5 days with maximum out to 76 days (Supplementary Fig. 2a). Time to giving infliximab did not correlate with the duration of colitis after receiving the infliximab (i.e. earlier infliximab does not equal shorter colitis for our cohort) (Supplementary Fig. 2b). Patients receiving two more doses of infliximab had no statistically significant difference in duration of diarrhoea (Supplementary Fig. 2c), although this could be confounded, and our study is not designed to answer this specific question. Treatment data were missing for two patients, so the treatment analysis includes 132 patients.

Figure 1d shows the treatment required for resolution of irAE colitis by immunotherapy type with combination therapy patients

Table 1. Clinical features and management outcomes of patients with ICI-related colitis. p value in column denotes differences between Group A, Group B and Group C by Kruskal–Wallis test for continuous data or chi-square test for categorical data.

|                                | Group A: Ipilimumab monotherapy (n = 189) | Group B: Anti-PD-1 monotherapy (n = 728) | Group C: Combination ipilimumab and nivolumab (n = 157) | p value | Total |
|--------------------------------|------------------------------------------|----------------------------------------|------------------------------------------------------|----------|-------|
| Patients with colitis (n, %)   | 42 (22)                                  | 41 (6)                                 | 51 (32)                                              | 2 x 10^-23 | 134 (13) |
| Onset of colitis since start of treatment (median days, interquartile range) | 64 (35–91)                              | 69 (29–150)                            | 40 (20–65)^*††                                       | <0.05   | 60 (28–88) |
| Median age of colitis patients (years, interquartile range) | 67 (57–76)                              | 70 (58–76)                             | 63 (56–68)                                           | <0.05   | 66 (57–72) |
| Male sex in colitis patients (n, %) | 28 (67)                                 | 23 (56)                                | 30 (59)                                              | 0.95     | 81 (60) |
| Colitis patients with hospital admission | 17 (40)                                 | 19 (46)                                | 38 (75)                                              | <0.0001  | 64 (48) |
| Days to first admission from onset of diarrhoea (Median, interquartile range) | 4 (3–6)                                 | 3 (0–5)                                | 5 (3–10)††                                           | <0.05   | 4 (3–7) |
| Time from colitis onset to endoscopy (Median, interquartile range) | 12 (4–18)                               | 5 (3–8)                                | 6 (3–10)                                              | 0.37     | 5 (3–9) |
| Length of first hospital stay in days for patients requiring admission (median, interquartile range) | 4 (3–8)                                 | 5 (3–8)                                | 6 (3–10)                                              |          |         |
| Treatment                        |                                          |                                        |                                                      |          |       |
| Any steroids (n, %)              | 38 (90)                                  | 29 (71)                                | 50 (98)                                              | <0.001   | 117 (87) |
| IV steroids (n, %)               | 12 (29)                                  | 14 (34)                                | 38 (75)                                              | <0.001   | 58 (43) |
| Days of IV steroids in those receiving (median, interquartile range) | 3 (2–4)                                 | 5 (3–8)                                | 4 (3–6)                                              | 0.16     | 4 (3–6) |
| Total days on any steroids (median, interquartile range) | 59 (51–92)                               | 60 (31–102)                            | 66 (49–117)                                          | 0.53     | 62 (47–100) |
| Infliximab (n, % total)          | 4 (10)                                   | 8 (20)                                 | 17 (33)                                              | <0.01    | 29 (22) |
| Colectomy (n, % total)           | 2 (5)                                    | 0 (0)                                  | 1 (2)                                                | 0.35     | 3 (2)   |

Note patients who had anti-PD-1 therapy then anti-CTLA-4 therapy sequentially (or vice versa) because of progression on first-line treatment were recorded as monotherapy at the time of colitis.

n/a not applicable.

^*p < 0.01 compared with Group B by Mann—Whitney test.

††p < 0.05 compared with Group A by Mann—Whitney test with Bonferroni correction.
Immune checkpoint inhibitor-related colitis assessment and prognosis: can... VTF Cheung et al.

A sub-group analysis showed that there was no difference in overall survival between those that developed irAE colitis and those that did not, nor in those that had infliximab and those that did not (Supplementary Fig. 6).

CTCAE as predictor of disease severity and clinical course
CTCAE classification of diarrhoea correlates poorly with duration of steroids and infliximab requirement, which were used as indirect markers of irAE colitis severity. In this analysis the CTCAE was only able to differentiate patients with G1 diarrhoea from the remainder of patients in terms of duration of steroids (Fig. 2a). There was no statistical association between CTCAE grade of diarrhoea and infliximab requirement (Fig. 2b). Seventy percent of our cohort were recorded as having moderate diarrhoea (G2/3), which afforded little discriminatory prognostic value (Fig. 2c). Immunotherapy toxicity guidelines12–14 and local treatment protocols advise escalation to infliximab for grade 3/4 colitis if symptoms persist despite corticosteroids beyond 72 h. In line with expectations, these patients were therefore more likely to be treated with infliximab (Fig. 2d). However, as with CTCAE grade of diarrhoea, the CTCAE grade of colitis was unable to prognosticate between grades 2, 3 and 4 of colitis in terms of duration of steroids (Fig. 2e). Figure 2f shows the proportion of patients with each CTCAE grade of colitis and this is similar to the breakdown by CTCAE grade of diarrhoea.

Fig. 1  Presentation and treatment of immunotherapy-induced (irAE) colitis in this cohort (n = 1074) of patients. a The incidence of colitis in single vs. combination immunotherapy (9% vs. 32%; Fisher’s exact test: p < 0.0001). b Onset of colitis after immunotherapy initiation (median 40 days in combination therapy vs. 68 days in monotherapy; Mann–Whitney test: p = 0.001). c 22% or 29 patients required infliximab for resolution of their colitis. Median duration of steroids in those who were treated with steroids alone was 50 days. d Number of patients requiring steroids monotherapy vs. steroids plus infliximab rescue therapy for treatment of their colitis; subdivided by immunotherapy regimen. Percentages requiring infliximab denoted in figure. Chi-squared test: p = 0.005 for difference between the CTLA4 and the combination therapy groups. e Mean duration of steroids in patients whose colitis responded to steroid monotherapy alone (patients requiring infliximab excluded); subdivided by immunotherapy regimen (median 56 days in anti-CTLA-4, 25 days in anti-PD-1, 54 days in combination; ANOVA: p = 0.04) (N.B. Data unavailable for 50% of patients in the aCTLA4 cohort).
Fig. 2 CTCAE as predictor of disease severity and clinical course. a Duration of steroids by CTCAE grade of diarrhoea shows difference between G1 and higher (G1 median 27 days, G2 64 days, G3 64 days, G4 73 days) (Kruskal–Wallis test: p = 0.002) but no difference between other grades (Kruskal–Wallis: p = 0.92) (N.B. Treatment duration data not available for 15% (20) of patients). b Requirement for infliximab by CTCAE grade of diarrhoea shows no difference (chi-squared test: p = 0.18). c Proportion of patients by CTCAE grade of diarrhoea. d Requirement for infliximab by CTCAE grade of colitis shows patients with grade 3/4 colitis were more likely to be treated with infliximab than those with grade 1/2 (Fisher’s exact: p < 0.0001). e Duration of steroids by CTCAE grade of colitis shows difference between G1 and higher (G1 median 22 days, G2 58 days, G3 85 days, G4 65 days) (Kruskal–Wallis test: p = 0.002) but no difference between other grades (Kruskal–Wallis: p = 0.23). f Proportion of patients by CTCAE grade of colitis.

Blood parameters as predictor of disease severity and clinical course
CRP, albumin, and haemoglobin do not correlate with severity of irAE colitis (Fig. 3a–c). There were insufficient measures of faecal calprotectin in this dataset to be used as part of this analysis.

Endoscopic predictors of disease severity and clinical course
There was moderately good inter-observer correlation for both UCEIS (kappa = 0.51, SE = 0.09) and Mayo scores (kappa = 0.54, SE = 0.09) as assessed by Landis and Koch criteria. We found a reasonable correlation between both UCEIS and Mayo scores and clinical outcome (Fig. 4a, b), and this includes both steroid duration and infliximab use. Erosions were most strongly associated with infliximab requirement (odds ratio 7.0) (Fig. 4c). The discordance between the CRP and albumin and the UCEIS score (Fig. 4d, e) within the subset of patients who underwent sigmoidoscopy further supports the finding that traditional biochemical markers used in idiopathic IBD are of limited use in the assessment of irAE colitis. Figure 4f demonstrates some typical endoscopic findings in irAE colitis.

Histologic predictors of disease severity and clinical course
Figure 5a shows the spectrum of histological subtypes seen in irAE colitis. None of the irAE colitis patients had prior NSAID use or had infection, so the NSAID/ infectious-like type histology classification is for those patients who had histological features consistent with a NSAID-related colitis or an infectious colitis. Our data demonstrate a modest correlation between endoscopic severity (as measured by UCEIS score) and histologic severity (as measured by Nancy index; Fig. 5b).

Of the microscopic colitis patients, four had collagenous colitis (one had UCEIS 0, two had UCEIS 1 and one had UCEIS 3) and nine had lymphocytic colitis (two had UCEIS 0, one had UCEIS 1, five had UCEIS 2 and one had UCEIS 4). Therefore, only three patients with microscopic colitis histologic pattern had completely normal endoscopic appearances. There were a further eight patients with UCEIS/ Mayo score of 0 who had mild histological inflammation—two focal active colitis, three IBD-like and three NSAID/ infectious-like.

There is a trend towards those having IBD-like pattern or NSAID/ infectious-like pattern being more likely to require infliximab rather than responding to steroids alone (Fig. 5c). None of the patients in our cohort had granulomas. Those patients with a higher Nancy index score (3 and 4) were significantly more likely to require infliximab (Fig. 5d).

DISCUSSION
We present a retrospective review of 1074 patients given ICI over a 7-year period in two large tertiary centres with 12% developing colitis (consistent with trial data).

Our data suggest that there are no pre-treatment predictive factors that associate with risk of irAE colitis. We confirm that combination ICI is associated with a higher incidence of
**Fig. 3**  **Biochemical markers as predictor of disease severity and clinical course.**  

a) C-reactive protein by treatment required for resolution of colitis (ANOVA: \( p = 0.12 \)).  
b) Haemoglobin by treatment required for resolution of colitis (ANOVA: \( p = 0.45 \)).  
c) Albumin by treatment required for resolution of colitis (ANOVA: \( p = 0.14 \)).

---

**Fig. 4**  **Endoscopic predictors of disease severity and clinical course.**  
Patients classified by the treatment required for the resolution of their colitis into three groups—steroid monotherapy <60 days, steroid monotherapy >60 days, or requirement for infliximab in addition to steroids. UCEIS and Mayo scores as assessed by two independent assessors (\( \kappa = 0.51, 0.54 \) respectively).  

**Fig. 4a**  UCEIS score at endoscopy vs. clinical outcome  

**Fig. 4b**  Mayo score at endoscopy by clinical outcome  

**Fig. 4c**  Erosions at endoscopy predict treatment required for resolution of colitis  

**Fig. 4d**  Correlation between UCEIS score and serum CRP in colitis  

**Fig. 4e**  Correlation between UCEIS score and serum albumin in colitis  

**Fig. 4f**  Characteristic endoscopy appearances during irAE colitis and after resolution. UCEIS ulcerative colitis endoscopic index of severity score, CRP C-reactive protein, irAE immunotherapy-related adverse events.
irAE colitis, earlier presentation and an increased requirement for intravenous steroids and infliximab. We demonstrate for the first time that there is no association between colitis development and smoking status.

The current CTCAE gradings for irAE diarrhoea and colitis, which are heavily reliant on subjective symptom scores, are not accurate enough to be relied on alone as tools for diagnosis and treatment decisions. This has implications for existing clinical guidelines and trial design. Patients with G1 diarrhoea or colitis are more likely to require a shorter duration of steroids, but otherwise CTCAE diarrhoea grades are unable to clearly discriminate steroid responsiveness or infliximab use. CTCAE colitis grades 3/4 do associate with a more severe macroscopic appearance may prompt clinicians to use infliximab seven-fold, complementing previous reports.\(^{27,28}\)

In our retrospective analysis, endoscopic assessment of irAE colitis is predictive of treatment outcome. Both UCEIS and Mayo scores correlate with steroid duration and need for infliximab. The presence of erosions at endoscopy increases the odds of requiring infliximab five-fold, complementing previous reports.\(^{27,28}\)

We have demonstrated for the first time that an objective UC histological score (Nancy Index) correlates with the clinical course of irAE colitis. Importantly the histology score is not purely a surrogate for endoscopic severity, as the relationship between the two is modest. Moreover, whilst the endoscopic scoring is open to the criticism of circular reasoning (a more severe macroscopic appearance may prompt clinicians to use infliximab), the histologic scoring was performed in blinded fashion after colitis resolution. The relationship between objective endoscopic and histologic scores and colitis outcome will need prospective testing, but our data suggest this will provide additional more accurate and objective information to clinicians. This is attractive given the current (and typically sole) use of CTCAE as the assessment and monitoring tool, as its objective performance is patchy at best.

The fact that patients treated with infliximab and steroids have an equally long course of steroids as those treated with steroid alone suggests that infliximab therapy, when used along current conventional guidelines, is only modestly effective. This may partly reflect the inadequacy of basing treatment decisions on CTCAE grade alone. Although some patients respond rapidly, there were a substantial number of patients in whom infliximab...
Immune checkpoint inhibitor-related colitis assessment and prognosis: can... VTF Cheung et al.

authors

V.T.F.C., T.G. and A.O.-B. contributed equally to the manuscript and should be considered joint first authors. V.T.F.C. and O.B. devised the article. V.T.F.C., T.G., S.C.S., A.O.-B., J.H., S.S., and J.J.S. collected the data. V.T.F.C., T.G., S.C.S. and O.B. analysed the data and drafted the original article. M.R.M., M.J.P., B.P.F., M.T., A.S.P., M.C., J.J.S., M.P., A.O.-B., J.H., O.B. and V.T.F.C. were involved in the clinical management of the patients. V.T.F.C. and O.B. scored the endoscopies independently. V.T.F.C., T.G., A.O.-B., S.S., S.C.S., J.H., E.F., E.C., J.J.S., M.P., A.S., P.K., M.T., A.S.P., M.C., B.P.F., M.J.P., M.R.M. and O.B. edited and contributed to the intellectual content of this original article and reviewed the article prior to submission.

additional information

Ethics approval and consent to participate This research forms part of the preliminary work for the ethics-approved Predicting Immunotherapy Side Effects (PRISE) Study (London-Surrey Research Ethics Committee: REC18/LO/0412) and the ‘A Mechanistic Investigation into Drug and Chemical Induced Hypersensitivity Reactions (HYST)’ study (REC12/NW/0525). The patients who had endoscopy assessment in Oxford also consented to participation within the ‘Gastrointestinal illness in Oxford: prospective cohort for outcomes, treatment, predictors and biobanking’ (16/1Y/ 0247). Appropriate Caldicott approvals are in place. The study was performed in accordance with the Declaration of Helsinki.

Consent to publish All patients starting immune checkpoint inhibitors gave written informed consent for their clinical data to be used for teaching and publications within the remit of the Oxford University Hospital Trust GI Biobank or the Clatterbridge Cancer Centre Biobank, which have been approved by institutional ethics committees.

Data availability The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials. Supplementary information is available at the British Journal of Cancer’s website.

Competing interests V.T.F.C. has received speaker fees from Janssen. A.O.-B. is an MRC Clinical Training Fellow based at the University of Liverpool supported by the North West England Medical Research Council Fellowship Scheme in Clinical Pharmacology and Therapeutics, which is funded by the Medical Research Council, Roche Pharma, Eli Lilly and Company Limited, UCB Pharma, Novartis, the University of Liverpool and the University of Manchester. She has received honoraria for speaking at educational events from Roche Pharma, Bristol-Myers-Squibb (BMS) and MSD. She has received honoraria for attendance at BMS advisory boards. J.J.S. has received speaker fees from BMS and Pierre Fabre; acted as a consultant for BMS, MSD, Amgen, Delacth and Immunocore; and his institution has received research grants from BMS and AZ. M.P. is the director of the North West England Medical Research Council Fellowship Scheme in Clinical Pharmacology and Therapeutics. M.R.M. has acted as a consultant for Amgen, AstraZeneca, Bristol-Myers Squibb, Eisai, GlaxoSmithKline, Immunocore, Lilly, Merck, Millennium, Novartis, Physiomics, Rigontec, and Roche; his institution has received research grants from Abbvie, Amgen, AstraZeneca, Bristol-Myers Squibb, Clovis, Eisai, GlaxoSmithKline, Immunocore, Merck, Millennium, Novartis, Pfizer, Rigontec, Roche, and Vertex. O.B. has received speaker fees from BMS and has received a research grant from Celgene. M.T. has performed Advisory/Consultancy work for Pfizer, Novartis, Lilly, Janssen, Roche, Vaccitec, BMS, and has been a paid speaker for and received paid speaking engagements and education support from Novartis, Pfizer, Roche, Janssen, BMS, Genomic Health, Astellas, Eisai, Everything Genetics. A.P. has received honoraria from Ipsen, Roche Bayer, Merck and BMC; and has received non-financial support from Ipsen and grants from Merck. The other authors have no conflicts of interest.

funding information The research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. V.T.F.C. is funded by grants from the Norman Collison Foundation and Oxfordshire Health Services Research Committee (OHSRC), part of Oxford Hospitals Charity. T.G. is supported by a clinical training fellowship from the Lee Placito Fund. S.C.S. is funded by an Oxford-Celgene Postdoctoral Fellowship. B.P.F. is supported by a Wellcome Intermediate Clinical Fellowship (201488/Z/16/Z). A.O.-B. is supported by a Medical Research Council (MRC) Clinical Research Fellowship (MR/N025989/1). A.S. is supported by a Wellcome Investigator Award and UK Medical Research Council.

supplementary information is available for this paper at https://doi.org/10.1038/s41416-020-0882-y.
REFERENCES

1. Wolchok, J., Kluger, H., Callahan, M., Postow, M., Rizvi, N., Lesokhin, A. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133 (2013).

2. Hodi, F., O'Day, S., McDermott, D., Weber, R., Sosman, J., Haanen, J. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

3. Garon, E., Rizvi, N., Hui, R., Leighl, N., Balmanoukian, A., Eder, J. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028 (2015).

4. Motzer, R., Escudier, B., McDermott, D., George, S., Hammers, H., Srinivas, S. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).

5. Herbst, R., Soria, J.-C., Powanetz, M., Fine, G., Hamid, O., Gordon, M. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).

6. Mariotto, A., Yabroff, K., Shao, Y., Feuer, E. & Brown, M. Projections of the cost of cancer care in the United States: 2010–2020. J. Natl. Cancer Inst. 103, 117–128 (2011).

7. Webster, R. The immune checkpoint inhibitors: where are we now? Nat. Rev. Drug Discov. 13, 883–884 (2014).

8. Cheung, V., Gupta, T., Payne, M., Middleton, M., Collier, J., Simmons, A. et al. Immunotherapy-related hepatitis: real-world experience from a tertiary centre. Frontline Gastroenterol. 10, 364–371 (2019).

9. Michot, J., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S. et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139–148 (2016).

10. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J., Covey, C., Lao, C. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).

11. U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). Version 5.0 (2017). https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.

12. Haanen, J., Carbonnel, F., Robert, C., Kerr, K., Peters, S., Larkin, J. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for oncology. Ann. Oncol. 28(suppl_4), iv119–iv142 (2017).

13. Brahmer, J., Laczketti, C., Schneider, A., Atkins, M., Byrd, D., Coltomel, J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J. Clin. Oncol. 36, 1714–1768 (2018).

14. Puzanov, I., Diab, A., Abdallah, K., Bingham, C., Brogdon, C., Dadu, R. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 5, 95 (2017).

15. Truelove, S., Cortisone in ulcerative colitis final report on a therapeutic trial. Br. Med. J. 2, 1041–1048 (1955).

16. Travis, S., Farrant, J., Ricketts, C., Nolan, D., Mortensen, N., Kettlewell, M. et al. Predicting outcome in severe ulcerative colitis. Gut 38, 905–910 (1996).

17. Travis, S., Schnell, D., Krzeski, P., Abreu, M., Altman, D., Colombel, J. et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 145, 987–995 (2013).

18. Corte, C., Fernandopulle, N., Catuneau, A., Burger, D., Cesarini, M., White, L. et al. Association between the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and outcomes in acute severe ulcerative colitis. J. Crohns Colitis 9, 376–381 (2015).

19. Marchal-Brennent, A., Salleron, J., Boualnagronombi, B., Bastien, C., Cahn, V., Cadot, G. et al. Development and validation of the Nancy histological index for UC. Gut 66, 43–49 (2017).

20. Ponte, A., Pinho, R., Fernandes, S., Rodrigues, A., Alberto, L., Silva, J. et al. Impact of histological and endoscopic remissions on clinical recurrence and recurrence-free time in ulcerative colitis. Inflamm. Bowel Dis. 23, 2238–2244 (2017).

21. Abu-Sheh, H., Ali, F., Luo, W., Qiao, W., Raju, G. & Wang, Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J. Immunother. Cancer 6, 95 (2018).

22. Wang, Y., Abu-Sheh, H., Miao, E., Ali, N., Qiao, W., Trinh, V. et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm. Bowel Dis. 24, 1695–1705 (2018).

23. Ho, G., Mowat, C., Goddard, C., Fennell, J., Shah, N., Prescott, R. et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment. Pharm. Ther. 19, 1079–1087 (2004).

24. Travis, S., Schnell, D., Krzeski, P., Abreu, M., Altman, D., Colombel, J. et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 61, 535–542 (2012).

25. Schroeder, K., Tremaune, W. & Istrup, D. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 317, 1625–1629 (1987).

26. Abu-Sheh, H., Al, F., Wang, X., Mallepally, N., Chen, E., Altman, M. et al. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J. Immunother. Cancer 7, 93 (2019).

27. Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Grinh, H., Kinhult, S. et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol. Immunother. 66, 581–592 (2017).

28. Jain, A., Lipson, E., Sharfman, W., Brant, S. & Lazarov, M. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. World J. Gastroenterol. 23, 2023–2028 (2017).

29. Geukses Foppen, S., Rozeman, E., van Wilpe, S., Postma, C., Snaebjornsson, P., van Thienen, J. et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 3, e000278 (2018).

30. Cheung, V., Gupta, T., Olsson-Brown, A., Subramanian, S., Sasson, S., Heseltine, J. et al. P272 Immune checkpoint inhibitor-related colitis assessment and prognosis: can inflammatory bowel disease scoring point the way? J. Crohns Colitis 14, 5286–5288 (2020).